Effects of IGF-I, alone and in combination with 17 beta-oestradiol, on bone remodelling parameters in ovariectomised rats.
We studied the effects of recombinant human IGF-I (250 micrograms/day) and/or 17 beta-oestradiol (E2; 5 or 50 micrograms/kg/day), s.c., for 28 days, on plasma IGF-I and 1,25-(OH)2 vitamin D3 concentrations and on biochemical indices of bone remodelling (plasma osteocalcin, urinary pyridinolines) in 3 month-old rats that had been ovariectomised (OVX) 6 weeks before. Ten weeks after ovariectomy, plasma 1,25-(OH)2D3 was increased, but IGF-I and bone remodelling indices were within the normal range. RhIGF-I administration to OVX rats increased both IGF-I and 1,25-(OH)2D3 concentrations, as well as plasma osteocalcin and urinary pyridinoline excretion. By contrast, E2 decreased plasma IGF-I and 1,25-(OH)2D3 and the markers of bone remodelling. The combination of rhIGF-I and E2 resulted in intermediate effects. Multiple regression analysis showed that IGF-I correlated with plasma osteocalcin, and also with the urinary excretion of pyridinolines. The data shows that rhIGF-I stimulates bone remodelling in growing OVX rats, and that circulating IGF-I is a determinant of bone remodelling in vivo.